Should quinolones come first in Helicobacter pylori therapy?

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 2, 2011, Pages 103-114

  Berning, Marco ^a   Krasz, Susanne ^a   Miehlke, Stephan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Helicobacter pylori; Levofloxacin; Moxifloxacin; Quinolones; Sitafloxacin; Therapy; Treatment

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BISMUTH; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NORFLOXACIN; OMEPRAZOLE; PEFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TINIDAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PHOTOTOXICITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN MANIFESTATION; TENDINITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 79953307249     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X10384171     Document Type: Review

References (64)

1. Ahuja V. Dhar A. Bal C. Sharma M.P. (1998) Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 12: 551–555.
2. Antos D. Schneider-Brachert W. Bästlein E. Hänel C. Haferland C. Buchner M. et al (2006) 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 11: 39–45.
3. Bago J. Majstorovic K. Belosic-Halle Z. Kucisec N. Bakula V. Tomic M. et al (2010) Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days moxifloxacin based therapy for the eradication: A randomized controlled trial. Ann Clin Microbiol Antimicrob 9: 13–13.
4. Bago J. Pevec B. Tomić M. Marusić M. Bakula V. Bago P. (2009) Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: A randomized controlled trial. Wien Klin Wochenschr 121: 47–52.
5. Bago P. Vcev A. Tomic M. Rozankovic M. Marusić M. Bago J. (2007) High eradication rate of H. pylori with moxifloxacin-based treatment: A randomized controlled trial. Wien Klin Wochenschr 119: 372–378.
6. Bauernfeind A. (1997) Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40: 639–651.
7. Berning M. Krasz S. Schneider-Brachert W. Madisch A. Laass M. Knoth H. et al (2009) Randomized multicenter study of esomeprazole, moxifloxacin and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection – impact of treatment duration. Gastroenterology 136(Suppl 1): 979–979.
8. Bilardi C. Dulbecco P. Zentilin P. Reglioni S. Iiritano E. Parodi A. et al (2004) A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial. Clin Gastroenterol Hepatol 2: 997–1002.
9. Bogaerts P. Berhin C. Nizet H. Glupczynski Y. (2006) Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11: 441–445.
10. Cammarota G. Cianci R. Cannizzaro O. Cuoco L. Pirozzi G. Gasbarrini A. et al (2000) Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1339–1343.
11. Carothers J.J. Bruce M.G. Hennessy T.W. Bensler M. Morris J.M. Reasonover A.L. et al (2007) The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 44: 5–8.
12. Castro-Fernández M. Lamas E. Pérez-Pastor A. Pabón M. Aparcero R. Vargas-Romero J. et al (2009) Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate. Helicobacter pylori. Rev Esp Enferm Dig 101: 395–398.
13. Cattoir V. Nectoux J. Lascols C. Deforges L. Delchier J.C. Megraud F. et al (2007) Update on fluoroquinolone resistance in Helicobacter pylori: New mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 29: 389–396.
14. Chang W.L. Sheu B.S. Cheng H.C. Yang Y.J. Yang H.B. Wu J.J. (2009) Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24: 1230–1235.
15. Cheon J.H. Kim N. Lee D.H. Kim J.M. Kim J.S. Jung H.C. et al (2006) Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 11: 46–51.
16. Chey W.D. Wong B.C. (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102: 1808–1825.
17. Chisholm S.A. Owen R.J. (2009) Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. J Med Microbiol 58: 1322–1328.
18. Della Monica P. Lavagna A. Masoero G. Lombardo L. Crocella L. Pera A. (2002) Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 16: 1269–1275.
19. de Sarro A. de Sarro G. (2001) Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 8: 371–384.
20. Deshpande A. Pant C. Jain A. Fraser T.G. Rolston D.D. (2008) Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 24: 329–333.
21. Di Caro S. Franceschi F. Mariani A. Thompson F. Raimondo D. Masci E. et al (2009) Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 41: 480–485.
22. Di Caro S. Ojetti V. Zocco M.A. Cremonini F. Bartolozzi F. Candelli M. et al (2002 a) Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 16: 527–532.
23. Di Caro S. Zocco M.A. Cremonini F. Candelli M. Nista E.C. Bartolozzi F. (2002 b) Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 14: 1309–1312.
24. Essa A.S. Kramer J.R. Graham D.Y. Treiber G. (2009) Meta-analysis: Four-drug, three-antibiotic, non-bismuth-containing ‘concomitant therapy’ versus triple therapy for Helicobacter pylori eradication. Helicobacter 14: 109–118.
25. Fennerty M.B. Lieberman D.A. Vakil N. Magaret N. Faigel D.O. Helfand M. (1999) Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 159: 1562–1566.
26. Fischbach W. Malfertheiner P. Hoffmann J.C. Bolten W. Bornschein J. Götze O. et al (2009) S3-guideline ‘helicobacter pylori and gastroduodenal ulcer disease’ of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e.V., German Society for Rheumatology. Z Gastroenterol 47: 1230–1263.
27. Gatta L. Zullo A. Perna F. Ricci C. de Francesco V. Tampieri A. et al (2005) A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 22: 45–49.
28. Gisbert J.P. Bermejo F. Castro-Fernández M. Pérez-Aisa A. Fernández-Bermejo M. Tomas A. et al (2008) Second-line rescue therapy with levofloxacin after H. pylori treatment failure: A Spanish multicenter study of 300 patients. Am J Gastroenterol 103: 71–76.
29. Gisbert J.P. Bermejo M.F. Infante J.M. Gallardo B.P. Bermejo A.B. Rodríguez J.M. et al (2009) Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol 43: 384–385.
30. Gisbert J.P. Fernández-Bermejo M. Molina-Infante J. Pérez-Gallardo B. Prieto-Bermejo A.B. Mateos-Rodríguez J.M. et al (2007) First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 26: 495–500.
31. Gisbert J.P. Gisbert J.L. Marcos S. Olivares D. Pajares J.M. (2006) Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 22: 1041–1046.
32. Gisbert J.P. Morena F. (2006) Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23: 35–44.
33. Gisbert J.P. Pérez-Aisa A. Castro-Fernández M. Barrio J. Rodrigo L. Cosme A. et al (2010) Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 42: 287–290.
34. Glocker E. Stueger H.P. Kist M. (2007) Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 51: 346–349.
35. Gupta V.K. Dhar A. Srinivasan S. Rattan A. Sharma M.P. (1997) Eradication of H. pylori in a developing country: Comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 92: 1140–1142.
36. Heep M. Kist M. Strobel S. Beck D. Lehn N. (2000) Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19: 538–541.
37. Hung K.H. Sheu B.S. Chang W.L. Wu H.M. Liu C.C. Wu J.J. (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a university hospital in Southern Taiwan. Helicobacter 14: 61–65.
38. Iacopini F. Crispino P. Paoluzi O.A. Consolazio A. Pica R. Rivera M. et al (2005) One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 37: 571–576.
39. Jafri N.S. Hornung C.A. Howden C.W. (2008) Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med 148: 923–931.
40. Kang J.M. Kim N. Lee D.H. Park Y.S. Kim Y.R. Kim J.S. et al (2007) Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 12: 623–628.
41. Kiliç Z.M. Köksal A.S. Cakal B. Nadir I. Ozin Y.O. Kuran S. et al (2008) Moxifloxacin plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 53: 3133–3137.
42. Liou J.M. Lin J.T. Chang C.Y. Chen M.J. Cheng T.Y. Lee Y.C. et al (2010) Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design. Gut 59: 572–578.
43. Malfertheiner P. Megraud F. O'Morain C. Bazzoli F. El-Omar E. Graham D. et al (2007) Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 56: 772–781.
44. Marzio L. Coraggio D. Capodicasa S. Grossi L. Cappello G. (2006) Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 11: 237–242.
45. McCusker M.E. Harris A.D. Perencevich E. Roghmann M.C. (2003) Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 9: 730–733.
46. Mera R.M. Beach K.J. Powell G.E. Pattishall E.N. (2010) Semi-automated risk estimation using large databases: Quinolones and Clostridium difficile associated diarrhea. Pharmacoepidemiol Drug Saf 19: 610–617.
47. Miehlke S. Schneider-Brachert W. Kirsch C. Morgner A. Madisch A. Kuhlisch E. et al (2008) One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13: 69–74.
48. Miyachi H. Miki I. Aoyama N. Shirasaka D. Matsumoto Y. Toyoda M. et al (2006) Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11: 243–249.
49. Molina-Infante J. Perez-Gallardo B. Fernandez-Bermejo M. Hernandez-Alonso M. Vinagre G. Dueñas C. et al (2010) Clinical trial: Clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 31: 1077–1084.
50. Nista E.C. Candelli M. Zocco M.A. Cazzato I.A. Cremonini F. Ojetti V. et al (2005) Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 1241–1247.
51. Nista E.C. Candelli M. Zocco M.A. Cremonini F. Ojetti V. Finizio R. et al (2006) Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101: 1985–1990.
52. Perna F. Zullo A. Ricci C. Hassan C. Morini S. Vaira D. (2007) Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance. Dig Liver Dis 39: 1001–1005.
53. Rispo A. Di Girolamo E. Cozzolino A. Bozzi R. Morante A. Pasquale L. (2007) Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 12: 364–365.
54. Romano M. Iovene M.R. Russo M.I. Rocco A. Salerno R. Cozzolino D. et al (2008) Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 61: 1112–1115.
55. Saad R.J. Schoenfeld P. Kim H.M. Chey W.D. (2006) Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis. Am J Gastroenterol 101: 488–496.
56. Sacco F. Spezzaferro M. Amitrano M. Grossi L. Manzoli L. Marzio L. (2009) Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig Liver Dis 42: 110–114.
57. Schrauwen R.W. Janssen M.J. de Boer W.A. (2009) Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 67: 96–101.
58. Sezgin O. Altintaş E. Uçbilek E. Tombak A. Tellioğlu B. (2007) Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: In an observational study in a Turkish population. Helicobacter 12: 518–522.
59. Tankovic J. Lascols C. Sculo Q. Petit J.C. Soussy C.J. (2003) Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47: 3942–3944.
60. Wang L.H. Cheng H. Hu F.L. Li J. (2010) Distribution of gyrA mutations in fluoroquinolone-resistant WHelicobacter pylori strains. World J Gastroenterol 16: 2272–2277.
61. Wang W.H. Wong B.C. Mukhopadhyay A.K. Berg D.E. Cho C.H. Lai K.C. et al (2000) High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 14: 901–910.
62. Wong W.M. Gu Q. Lam S.K. Fung F.M. Lai K.C. Hu W.H. et al (2003) Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 17: 553–560.
63. Yoon H. Kim N. Lee B.H. Hwang T.J. Lee D.H. Park Y.S. et al (2009) Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 14: 77–85.
64. Zullo A. Perna F. Hassan C. Ricci C. Saracino I. Morini S. et al (2007) Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 25: 1429–1434.